[go: up one dir, main page]

HK1118229A1 - Human antibodies specific to kdr and uses thereof - Google Patents

Human antibodies specific to kdr and uses thereof Download PDF

Info

Publication number
HK1118229A1
HK1118229A1 HK08111919.7A HK08111919A HK1118229A1 HK 1118229 A1 HK1118229 A1 HK 1118229A1 HK 08111919 A HK08111919 A HK 08111919A HK 1118229 A1 HK1118229 A1 HK 1118229A1
Authority
HK
Hong Kong
Prior art keywords
kdr
antibody
seq
human
antibodies
Prior art date
Application number
HK08111919.7A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1118229B (en
Inventor
Zhenping Zhu
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27805075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1118229(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of HK1118229A1 publication Critical patent/HK1118229A1/en
Publication of HK1118229B publication Critical patent/HK1118229B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
HK08111919.7A 2002-03-04 2008-10-30 Human antibodies specific to kdr and uses thereof HK1118229B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36178302P 2002-03-04 2002-03-04
US361783P 2002-03-04

Publications (2)

Publication Number Publication Date
HK1118229A1 true HK1118229A1 (en) 2009-02-06
HK1118229B HK1118229B (en) 2011-09-23

Family

ID=

Also Published As

Publication number Publication date
EP1916001A3 (en) 2008-08-13
DK1487856T3 (da) 2010-10-18
EP1916001A2 (en) 2008-04-30
CY2015018I2 (el) 2016-04-13
WO2003075840A3 (en) 2004-04-29
AU2003213687A8 (en) 2003-09-22
DK1916001T3 (da) 2011-07-18
US20090142358A1 (en) 2009-06-04
HUS1500025I1 (hu) 2017-04-28
FR15C0034I1 (fr) 2015-06-26
SI1487856T1 (sl) 2010-12-31
JP4970483B2 (ja) 2012-07-04
EP1487856B1 (en) 2010-07-28
LU92710I2 (fr) 2015-11-02
JP2009148298A (ja) 2009-07-09
PT1487856E (pt) 2010-09-29
DE60333554D1 (de) 2010-09-09
CY2015018I1 (el) 2016-04-13
WO2003075840A2 (en) 2003-09-18
FR15C0034I2 (fr) 2016-08-26
JP2012105667A (ja) 2012-06-07
EP2298346A2 (en) 2011-03-23
CY1111629T1 (el) 2015-10-07
US20050234225A1 (en) 2005-10-20
US8057791B2 (en) 2011-11-15
JP2005526506A (ja) 2005-09-08
CA2478169C (en) 2013-04-16
BE2015C027I2 (el) 2022-05-19
CA2478169A1 (en) 2003-09-18
EP1487856A4 (en) 2006-08-23
AU2003213687A1 (en) 2003-09-22
ATE475431T1 (de) 2010-08-15
ES2362931T3 (es) 2011-07-15
ES2347543T3 (es) 2010-11-02
EP2298346A3 (en) 2011-11-16
EP1487856A2 (en) 2004-12-22
SI1916001T1 (sl) 2011-10-28
EP1916001B1 (en) 2011-05-25
ATE510561T1 (de) 2011-06-15
JP5476404B2 (ja) 2014-04-23
PT1916001E (pt) 2011-07-18
CY1111141T1 (el) 2015-06-11
US7498414B2 (en) 2009-03-03

Similar Documents

Publication Publication Date Title
EP1916001B1 (en) Human antibodies specific to KDR and uses thereof
EP1735348B1 (en) Human anti-epidermal growth factor receptor antibody
JP5086430B2 (ja) 血管内皮成長因子（ｖｅｇｆ）受容体を中和するヒトモノクローナル抗体及びその用途
US20090028859A1 (en) Bispecific antibodies that bind to vegf receptors
US20090022714A1 (en) Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US20050214860A1 (en) Antibodies specific to KDR and uses thereof
CZ20032586A3 (cs) Kombinované metody inhibice nádorového růstu s antagonistou receptoru vaskulárního endotelového růstového faktoru
WO2004003211A1 (en) Bispecific antibodies that bind to vegf receptors
HK1118229B (en) Human antibodies specific to kdr and uses thereof
AU2002248544A1 (en) Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230303